邻苯二甲酸酯暴露与乳腺癌发病率:一项丹麦全国性队列研究
高累积剂量邻苯二甲酸二丁酯暴露(≥10000 mg)与雌激素受体阳性乳腺癌发病率约增加两倍相关(HR 1.9,95%CI 1.1-3.5)。作者认为女性应避免高水平邻苯二甲酸二丁酯暴露。
要点
- 多数邻苯二甲酸酯暴露与乳腺癌发病无关。
- 高累积邻苯二甲酸二丁酯暴露(≥10000 mg)与雌激素受体阳性乳腺癌发病率约增加两倍相关(HR 1.9,95%CI 1.1-3.5)。
- 作者认为女性应避免高水平邻苯二甲酸二丁酯暴露,如长期使用含该成分的药品。
核心结论
- 研究结果提示女性应避免高水平邻苯二甲酸二丁酯暴露,例如通过长期使用含邻苯二甲酸二丁酯的药品。
主要发现
- 高累积邻苯二甲酸二丁酯暴露(≥10000 mg)与雌激素受体阳性乳腺癌发病率约增加两倍相关(HR 1.9,95%CI 1.1-3.5)。
- 较低水平的邻苯二甲酸二丁酯暴露与乳腺癌发病率无关。
临床怎么用
- 作者认为女性应避免高水平邻苯二甲酸二丁酯暴露,如通过长期使用含邻苯二甲酸二丁酯的药品。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Phthalate exposure is ubiquitous and especially high among users of drug products formulated with phthalates. Some phthalates mimic estradiol and may promote breast cancer. Existing epidemiologic studies on this topic are small, mostly not prospective, and have given inconsistent results. We estimated associations between longitudinal phthalate exposures and breast cancer risk in a Danish nationwide cohort, using redeemed prescriptions for phthalate-containing drug products to measure exposure. METHODS: We ascertained the phthalate content of drugs marketed in Denmark using an internal Danish Medicines Agency ingredient database. We enrolled a Danish nationwide cohort of 1.12 million women at risk for a first cancer diagnosis on January 1, 2005. By combining drug ingredient data with the Danish National Prescription registry, we characterized annual, cumulative phthalate exposure through redeemed prescriptions. We then fit multivariable Cox regression models to estimate associations between phthalate exposures and incident invasive breast carcinoma according to tumor estrogen receptor status. RESULTS: Over 9.99 million woman-years of follow-up, most phthalate exposures were not associated with breast cancer incidence. High-level dibutyl phthalate exposure (≥ 10,000 cumulative mg) was associated with an approximately two-fold increase in the rate of estrogen receptor-positive breast cancer (hazard ratio, 1.9; 95% CI, 1.1 to 3.5), consistent with in vitro evidence for an estrogenic effect of this compound. Lower levels of dibutyl phthalate exposure were not associated with breast cancer incidence. CONCLUSION: Our results suggest that women should avoid high-level exposure to dibutyl phthalate, such as through long-term treatment with pharmaceuticals formulated with dibutyl phthalate.
引用
- Ahern TP, Broe A, Lash TL, et al. Phthalate Exposure and Breast Cancer Incidence: A Danish Nationwide Cohort Study. J Clin Oncol. 2019. PMID: 30995175. doi:10.1200/JCO.18.02202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。